MOTS-c

Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide with the sequence MRWQEMGYIFYPRKLR, a molecular weight of 2,174.6 Da, and the molecular formula C₁₀₁H₁₅₂N₂₈O₂₂S₂. First described by Changhan David Lee and colleagues at the University of Southern California in a landmark 2015 publication in Cell Metabolism, MOTS-c represents a paradigm-shifting discovery: it is encoded within the mitochondrial genome rather than the nuclear genome, establishing a new class of signaling molecules called mitochondrial-derived peptides (MDPs).

Specifically, MOTS-c is encoded within the 12S ribosomal RNA gene of mitochondrial DNA. It is translated in the mitochondria and subsequently translocated to the cytoplasm and nucleus, where it modulates metabolic gene programs. This mitochondria-to-nucleus signaling pathway, termed retrograde signaling, represents a novel mechanism by which mitochondria communicate their metabolic status to nuclear transcriptional machinery.

MOTS-c has been characterized as an exercise mimetic, reproducing many of the metabolic adaptations associated with physical exercise, and has attracted significant attention in aging, metabolic disease, and longevity research.

Mechanism of Action

MOTS-c's primary mechanism centers on activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. AMPK activation occurs through an indirect pathway: MOTS-c inhibits the folate cycle and its tethered de novo purine biosynthesis pathway, leading to accumulation of the intermediate AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a known endogenous AMPK activator.

Downstream effects of MOTS-c-mediated AMPK activation include:

• Enhanced glucose uptake: Increased GLUT4 translocation to the cell membrane in skeletal muscle, improving glucose disposal independent of insulin signaling
• Fatty acid oxidation: Activation of carnitine palmitoyltransferase I (CPT1) and enhanced mitochondrial beta-oxidation of fatty acids
• Gluconeogenesis inhibition: Suppression of hepatic glucose production via downregulation of key gluconeogenic enzymes
• Mitochondrial biogenesis: Upregulation of PGC-1alpha and downstream mitochondrial transcription factors, increasing mitochondrial mass and oxidative capacity
• Nuclear translocation: Under metabolic stress, MOTS-c translocates to the nucleus where it interacts with transcription factors to regulate adaptive stress response genes, particularly those involved in antioxidant defense and metabolic adaptation

The primary target tissue appears to be skeletal muscle, consistent with MOTS-c's characterization as an exercise mimetic.

Research Evidence

The discovery paper by Lee et al. (2015; PMID: 25738459) in Cell Metabolism established MOTS-c as a mitochondrial-encoded peptide that promotes metabolic homeostasis and reduces obesity and insulin resistance. In this study, MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity, with effects mediated through AMPK-dependent skeletal muscle glucose metabolism.

A subsequent study published in Nature Communications (PMID: 33420021) demonstrated that MOTS-c functions as an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. This work showed that MOTS-c levels increase in skeletal muscle and plasma during exercise, and that exogenous MOTS-c administration improves physical performance and muscle homeostasis in aged mice.

Kim et al. (PMID: 31293078) demonstrated that MOTS-c regulates plasma metabolites and enhances insulin sensitivity, with metabolomic profiling revealing coordinated changes in amino acid metabolism, lipid metabolism, and energy metabolites consistent with improved metabolic flexibility.

Research by Zempo et al. identified a polymorphism in the MOTS-c-encoding region (m.1382A>C) that is associated with exceptional longevity in Japanese centenarians, suggesting that MOTS-c variants may contribute to human aging phenotypes (PMID: 36233287).

A comprehensive review by Kumagai et al. (PMID: 36677050) examined MOTS-c's role in metabolic disorder prevention, synthesizing evidence across obesity, diabetes, aging, and exercise physiology.

Potential Applications

• Metabolic syndrome and obesity: AMPK-mediated improvements in glucose disposal, lipid metabolism, and energy expenditure in preclinical models
• Type 2 diabetes: Insulin-sensitizing effects via enhanced skeletal muscle glucose uptake and suppressed hepatic gluconeogenesis
• Exercise mimetic applications: Potential to reproduce metabolic benefits of exercise in populations unable to engage in physical activity due to disability, frailty, or acute illness
• Aging and longevity: Age-dependent decline in MOTS-c levels correlates with metabolic deterioration, and exogenous supplementation restores youthful metabolic profiles in aged animal models
• Sarcopenia: Preservation of muscle mass and function in aging models through improved mitochondrial biogenesis and metabolic homeostasis
• Cardiovascular metabolism: Emerging evidence of cardioprotective effects via improved mitochondrial function in cardiac tissue

Safety Considerations

MOTS-c research is in the preclinical stage, with no completed human clinical trials as of 2026. Safety data are derived exclusively from animal studies, predominantly in murine models.

In preclinical studies, MOTS-c administration has been generally well tolerated in mice at doses used to achieve metabolic effects. As an endogenous mitochondrial-derived peptide present in human plasma, MOTS-c has theoretical biocompatibility advantages. However, the peptide's half-life in human plasma has not been formally characterized, and pharmacokinetic data in humans are absent.

Theoretical safety considerations include the potential for hypoglycemia via enhanced glucose uptake (particularly in combination with insulin or oral hypoglycemic agents), effects on purine biosynthesis that could influence rapidly dividing cell populations, and unknown consequences of chronic AMPK activation on tissue homeostasis. The folate cycle inhibition mechanism also raises questions about interactions with folate-dependent metabolic processes.

As a mitochondrially encoded peptide, population-level variation in mitochondrial DNA sequences could influence MOTS-c structure and function across different genetic backgrounds, a consideration that has not been fully explored. No regulatory approval exists for MOTS-c in any jurisdiction, and all findings should be interpreted as preclinical research observations.